Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Pryce

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Plos One|October 17, 2013
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosisSofia Sisay, Gareth Pryce, Samuel J Jackson, et al.
Journal of Neuroimmunology|June 2, 2005
Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH micePaul A Smith, Margaret Morris-Downes, Nicole Heijmans, et al.
Journal of Neuroimmunology|August 2, 2005
Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH miceNicole Heijmans, Paul A Smith, Margaret M Morris-Downes, et al.
Immunology|December 17, 2017
Alemtuzumab depletion failure can occur in multiple sclerosisNicolas Dubuisson, David Baker, Angray S Kang, et al.
European Journal of Pharmacology|January 28, 2004
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptakeEva de Lago, Alessia Ligresti, Giorgio Ortar, et al.
Journal of Neuroimmunology|August 2, 2008
An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal lossDavid W Hampton, Jane Anderson, Gareth Pryce, et al.
Frontiers in Immunology|March 3, 2020
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal AntibodiesDavid Baker, Liaqat Ali, Gauri Saxena, et al.
European Journal of Pharmacology|April 9, 2002
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptorsJason W Brooks, Gareth Pryce, Tiziana Bisogno, et al.
Brain : a Journal of Neurology|July 24, 2003
Cannabinoids inhibit neurodegeneration in models of multiple sclerosisGareth Pryce, Zubair Ahmed, Deborah J R Hankey, et al.
Immunology|July 9, 2016
Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH miceLaura A N Peferoen, Marjolein Breur, Sarah van de Berg, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Plos One|October 17, 2013
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosisSofia Sisay, Gareth Pryce, Samuel J Jackson, et al.
Journal of Neuroimmunology|June 2, 2005
Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH micePaul A Smith, Margaret Morris-Downes, Nicole Heijmans, et al.
Journal of Neuroimmunology|August 2, 2005
Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH miceNicole Heijmans, Paul A Smith, Margaret M Morris-Downes, et al.
Immunology|December 17, 2017
Alemtuzumab depletion failure can occur in multiple sclerosisNicolas Dubuisson, David Baker, Angray S Kang, et al.
European Journal of Pharmacology|January 28, 2004
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptakeEva de Lago, Alessia Ligresti, Giorgio Ortar, et al.
Journal of Neuroimmunology|August 2, 2008
An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal lossDavid W Hampton, Jane Anderson, Gareth Pryce, et al.
Frontiers in Immunology|March 3, 2020
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal AntibodiesDavid Baker, Liaqat Ali, Gauri Saxena, et al.
European Journal of Pharmacology|April 9, 2002
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptorsJason W Brooks, Gareth Pryce, Tiziana Bisogno, et al.
Brain : a Journal of Neurology|July 24, 2003
Cannabinoids inhibit neurodegeneration in models of multiple sclerosisGareth Pryce, Zubair Ahmed, Deborah J R Hankey, et al.
Immunology|July 9, 2016
Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH miceLaura A N Peferoen, Marjolein Breur, Sarah van de Berg, et al.
Pageof 7